Elevance Health Inc.

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +42

Elevance Health previews lower third-quarter earnings for Elevance Health stock

Earnings report Guidance raised AI-generated analysis

πŸ“‰ Elevance Health faces a challenging third-quarter comparison with adjusted earnings per share forecast at USD 4.72, down 21.70% from the prior year.

πŸ’° The company raised its full-year 2026 adjusted diluted earnings per share guidance to at least USD 27 and lifted operating cash flow guidance to at least USD 6 billion.

πŸ“Š Second-quarter operating revenue increased by 0.8% year over year to reach USD 49.80 billion, exceeding management's previous outlook.

πŸ₯ Medicaid operations are under pressure with elevated utilization and a full-year operating margin outlook of negative 1.75%.

πŸ“ˆ Management remains confident in achieving at least 12% adjusted earnings per share growth for fiscal year 2027.

πŸ“… The company has a market capitalization of USD 84.3 billion as of September 30, 2026, with its stock trading below the yearly high.

🎯 The upcoming October 21 earnings report will be critical for determining if second-half execution can offset year-over-year comparison pressure.

Bullish Signals
  • Elevance Health raised its full-year 2026 adjusted diluted earnings per share guidance to at least USD 27, signaling strong management confidence in future profitability.
  • The company lifted its operating cash flow guidance to at least USD 6 billion for the fiscal year, indicating robust liquidity generation.
  • Second-quarter operating revenue grew by 0.8% year over year to USD 49.80 billion, demonstrating resilience in a mixed market environment.
  • Management reaffirmed confidence in returning to at least 12% adjusted earnings per share growth in fiscal 2027.
Risk Factors
  • Analysts forecast third-quarter adjusted earnings per share of USD 4.72, which is a significant 21.70% decline compared to the USD 6.03 reported last year.
  • The Medicaid business unit faces elevated utilization and a full-year operating margin outlook of negative 1.75%, creating pressure on overall profitability.
Full Analysis
Elevance Health is preparing to report third-quarter earnings on October 21, 2026, with analysts forecasting adjusted earnings per share of USD 4.72. This figure represents a significant year-over-year decline compared to the USD 6.03 reported in the same quarter last year, driven primarily by elevated costs within its Medicaid portfolio. Despite the anticipated weakness in quarterly comparisons, management has raised its full-year 2026 adjusted diluted earnings per share guidance to at least USD 27 and increased operating cash flow guidance to at least USD 6 billion. The company maintains confidence in returning to at least 12% adjusted earnings per share growth in 2027. The second quarter showed mixed results with operating revenue growing modestly by 0.8% year over year to USD 49.80 billion, while medical membership ended at 44.9 million. The upcoming report will test whether strong second-half execution can offset the pressure from lower quarterly comparisons and persistent Medicaid margin challenges.